Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Early identification and treatment of patients with COPD at risk of exacerbation are crucial for better outcomes. Single-inhaler triple therapy (SITT) users showed improved exacerbation rates and ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation. It is important ...

The symptoms of COPD aren’t always obvious. Subtle signs like finding it harder to keep up with friends on a walk or unconsciously cutting down on physical activity can be easy to miss. Some people ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...

As of early 2026, COPD remains the fifth-leading cause of death nationwide and carries a substantial economic burden, with ...

There is not enough scientific evidence to support the use of nebulizing hydrogen peroxide as a treatment for chronic obstructive pulmonary disease (COPD), and it may have dangerous side effects. Some ...